Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

ClinicalTrials.gov ID: NCT01903837

Public ClinicalTrials.gov record NCT01903837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.

Study identification

NCT ID
NCT01903837
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
347 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2013
Primary completion
Nov 30, 2014
Completion
Feb 28, 2015
Last update posted
Oct 5, 2021

2013 – 2015

United States locations

U.S. sites
50
U.S. states
20
U.S. cities
46
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72211
Alkermes Investigational Site Anaheim California 92805
Alkermes Investigational Site Costa Mesa California 92626
Alkermes Investigational Site Culver City California 90230
Alkermes Investigational Site Escondido California 92025
Alkermes Investigational Site Garden Grove California 92845
Alkermes Investigational Site National City California 91950
Alkermes Investigational Site Oakland California 94612
Alkermes Investigational Site Oceanside California 92056
Alkermes Investigational Site Orange California 92868
Alkermes Investigational Site Pico Rivera California 90660
Alkermes Investigational Site San Diego California 92103
Alkermes Investigational Site Torrance California 90502
Alkermes Investigational Site New Britain Connecticut 06052
Alkermes Investigational Site Washington D.C. District of Columbia 20016
Alkermes Investigational Site Bradenton Florida 34208
Alkermes Investigational Site Fort Lauderdale Florida 33308
Alkermes Investigational Site Gainesville Florida 32607
Alkermes Investigational Site Kissimmee Florida 34741
Alkermes Investigational Site Leesburg Florida 34748
Alkermes Investigational Site Oakland Park Florida 33334
Alkermes Investigational Site Orlando Florida 32810
Alkermes Investigational Site Atlanta Georgia 30308
Alkermes Investigational Site Decatur Georgia 30030
Alkermes Investigational Site Chicago Illinois 60640
Alkermes Investigational Site Lake Charles Louisiana 70629
Alkermes Investigational Site Shreveport Louisiana 71101
Alkermes Investigational Site Rockville Maryland 20850
Alkermes Investigational Site Flowood Mississippi 39232
Alkermes Investigational Site Creve Coeur Missouri 63141
Alkermes Investigational Site St Louis Missouri 63118
Alkermes Investigational Site Marlton New Jersey 08053
Alkermes Investigational Site Neptune City New Jersey 07754
Alkermes Investigational Site Canton Ohio 44718
Alkermes Investigational Site Mason Ohio 45040
Alkermes Investigational Site Oklahoma City Oklahoma 73103
Alkermes Investigational Site Oklahoma City Oklahoma 73116
Alkermes Investigational Site Philadelphia Pennsylvania 19139
Alkermes Investigational Site Charleston South Carolina 29407
Alkermes Investigational Site Memphis Tennessee 38119
Alkermes Investigational Site Austin Texas 78731
Alkermes Investigational Site Austin Texas 78754
Alkermes Investigational Site Dallas Texas 75231
Alkermes Investigational Site Dallas Texas 75243
Alkermes Investigational Site DeSoto Texas 75115
Alkermes Investigational Site Houston Texas 77007
Alkermes Investigational Site Houston Texas 77008
Alkermes Investigational Site Salt Lake City Utah 84106
Alkermes Investigational Site Bellevue Washington 98007
Alkermes Investigational Site Richland Washington 99362

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01903837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2021 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01903837 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →